Serum Paraoxonase After Myocardial Infarction

A. Ayub, M. I. Mackness, S. Arrol, B. Mackness, J. Patel, P. N. Durrington
1999 Arteriosclerosis, Thrombosis and Vascular Biology  
HDL has been shown to prevent the oxidative modification of LDL. The antioxidant activity of HDL is believed to reside in its enzymes, particularly paraoxonase. Human serum paraoxonase (PON1) is closely associated with a specific HDL subfraction also containing apoA1 and clusterin. Recently PON1 has been implicated in the pathogenesis of atherosclerosis. We have examined the activity, concentration, and specific activity of PON1 in 50 patients on admission to hospital immediately after acute
more » ... cardial infarction (MI) and in 48 age-and gender-matched controls. Serum PON1 activity and concentration were significantly lower in patients with MI than in controls ( activity, 221.5 [99.3 to 303.2] nmol ⅐ min Ϫ1 ⅐ mL Ϫ1 in controls and 130.1 [78.9 to 230.3] nmol ⅐ min Ϫ1 ⅐ mL Ϫ1 in MI patients [PϽ0.05]; concentration, 95.7 [73.2 to 135.5] g/mL in controls and 35.4 [21.6 to 51.3] g/mL in MI patients [PϽ0.001]). PON1-specific activity was significantly higher in patients with MI than in controls (1.5 [0.9 to 2.9] versus 3.4 [2.0 to 8.5] nmol ⅐ min Ϫ1 ⅐ g Ϫ1 [PϽ0.001]) due to the much lower PON1 concentration. PON1 activity had risen significantly (PϽ0.05) to 158.1 (85.4 to 282 .0) nmol ⅐ min Ϫ1 ⅐ mL Ϫ1 at day 42 but was still significantly less than that of controls. No significant variation in PON1 concentration occured in the days after MI or at 6 weeks. Also, no significant variation in specific activity was seen after MI. When the patients were divided into subgroups based on whether or not they received thrombolytic therapy on admission to hospital, no significant difference in PON1 levels was observed. Serum HDL cholesterol in patients with MI on admission was not significantly different than in controls, and the decrease that occurred by the fifth day after MI did not explain the lower PON1 levels. We conclude that low serum PON1 activity in patients with MI may be a consequence of the coronary event itself or could have been present before MI. The low PON1 activity was also not explicable on the basis of PON1 genotypes because the prevalence of genotypes associated with low activity was not sufficient to explain fully the difference in activity levels between patients and controls. The explanation for the low PON1 activity was most likely a decrease in serum PON1 concentration. The importance of PON1 as a predictive risk factor for MI should be assessed in future studies. (Arterioscler Thromb Vasc Biol. 1999;19:330-335.)
doi:10.1161/01.atv.19.2.330 pmid:9974415 fatcat:53vbjscaszcznar345xdw7rfra